Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases
The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology Jg. 71; H. 5; S. 564 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
06.02.2018
|
| Schlagworte: | |
| ISSN: | 1558-3597, 1558-3597 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts. |
|---|---|
| AbstractList | The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts. The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts. |
| Author | Blank, Evan Heller, David J Kishore, Sandeep P Fuster, Valentin Huffman, Mark D Vidula, Mahesh Onuma, Oyere Vedanthan, Rajesh Peters, Alexander Price, Matthew Patel, Amisha |
| Author_xml | – sequence: 1 givenname: Sandeep P surname: Kishore fullname: Kishore, Sandeep P email: sandeep.kishore@mssm.edu organization: Arnhold Institute for Global Health, Department of Medicine/Health System Design & Global Health, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: sandeep.kishore@mssm.edu – sequence: 2 givenname: Evan surname: Blank fullname: Blank, Evan organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York – sequence: 3 givenname: David J surname: Heller fullname: Heller, David J organization: Arnhold Institute for Global Health, Department of Medicine/Health System Design & Global Health, Icahn School of Medicine at Mount Sinai, New York, New York – sequence: 4 givenname: Amisha surname: Patel fullname: Patel, Amisha organization: Department of Medicine-Cardiology, Columbia University/New York Presbyterian Hospital, New York, New York – sequence: 5 givenname: Alexander surname: Peters fullname: Peters, Alexander organization: Department of Surgery, Weill Cornell Medicine, New York, New York; Program in Global Surgery and Social Change, Harvard Medical School, Boston, Massachusetts; Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, Massachusetts – sequence: 6 givenname: Matthew surname: Price fullname: Price, Matthew organization: Independent Consultant, Baltimore, Maryland – sequence: 7 givenname: Mahesh surname: Vidula fullname: Vidula, Mahesh organization: Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts – sequence: 8 givenname: Valentin surname: Fuster fullname: Fuster, Valentin organization: Zena & Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York – sequence: 9 givenname: Oyere surname: Onuma fullname: Onuma, Oyere organization: Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention, World Health Organization, Chicago, Illinois – sequence: 10 givenname: Mark D surname: Huffman fullname: Huffman, Mark D organization: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois – sequence: 11 givenname: Rajesh surname: Vedanthan fullname: Vedanthan, Rajesh organization: Zena & Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29406862$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUM1KAzEYDFKxP_oCHiRHL12TbDfbHKVWK7TUg-KxfLv5tk1Jk5psCwq-i8_ik7nFCp5mhhkGZrqk5bxDQi45Szjj8madrKEsE8F4nnCesEyekA7PsmE_zVTe-sfbpBvjmjEmh1ydkbZQg4ZK0SGfM68xOPNh3JLWK6SvPlhNJwi2XtF5WELjQW28o1MTa-orOo4RXW3A0hlqUxqHkVY-fH89BdwfnKYJnKYj7-rgrT3oEQRt_B5iubMQ6J2JCBHjOTmtwEa8OGKPvNyPn0eT_nT-8Di6nfbLgWJ1v6hKzVGDQDnMRQ4olIIGqlQ242SRsgqA51kOQhVCs5RrrfJsABJSVshc9Mj1b-82-LcdxnqxMbFEa8Gh38UFV0pxJXjGm-jVMborNqgX22A2EN4Xf5eJH7p1dBw |
| CitedBy_id | crossref_primary_10_1016_j_ipha_2025_05_002 crossref_primary_10_1097_HJH_0000000000003169 crossref_primary_10_12677_PI_2020_91001 crossref_primary_10_1016_j_bcp_2025_117330 crossref_primary_10_1016_j_jphotobiol_2022_112622 crossref_primary_10_1016_j_vhri_2023_04_005 crossref_primary_10_1007_s11033_023_08246_2 crossref_primary_10_1136_bmjopen_2022_061350 crossref_primary_10_1186_s40545_022_00494_0 crossref_primary_10_3389_fphar_2022_997598 crossref_primary_10_3390_s20082386 crossref_primary_10_1371_journal_pmed_1003944 crossref_primary_10_5114_aoms_203474 crossref_primary_10_1016_j_ihj_2019_04_009 crossref_primary_10_1089_acm_2018_0212 crossref_primary_10_1016_j_bcp_2021_114406 crossref_primary_10_5334_gh_1310 crossref_primary_10_1016_j_jddst_2024_106200 crossref_primary_10_51507_j_jams_2021_14_6_207 crossref_primary_10_1016_j_colsurfa_2023_130998 crossref_primary_10_1371_journal_ppat_1007226 crossref_primary_10_1136_openhrt_2025_003548 crossref_primary_10_1097_MCA_0000000000000625 crossref_primary_10_1186_s12915_025_02345_1 crossref_primary_10_1186_s12872_024_03774_6 crossref_primary_10_1111_jch_13280 crossref_primary_10_1900_RDS_2021_17_57 crossref_primary_10_1007_s11302_022_09900_3 crossref_primary_10_1371_journal_pone_0241555 crossref_primary_10_3389_fphar_2020_00222 crossref_primary_10_1038_s41591_021_01635_9 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jacc.2017.11.056 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-3597 |
| ExternalDocumentID | 29406862 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: FIC NIH HHS grantid: R21 TW010452 – fundername: NHLBI NIH HHS grantid: R01 HL125487 – fundername: NHLBI NIH HHS grantid: R00 HL107749 – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AAEDT AAEDW AAIKJ AAKUH AALRI AAOAW AAQFI AAQQT AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABMZM ABOCM ACGFO ACGFS ACIUM ACJTP ACPRK ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFCTW AFETI AFPUW AFRAH AFRHN AFTJW AGCQF AGYEJ AHMBA AIGII AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EFKBS EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GBLVA GX1 H13 HVGLF IHE IXB J1W K-O KQ8 L7B MO0 N9A NPM O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ Q38 RIG ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R 7X8 EFLBG ~HD |
| ID | FETCH-LOGICAL-c490t-bfcd1eda2e68727ae299a7aef365976b30faa1757a29b2d031dd9754a6a30b672 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 38 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000423996800012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1558-3597 |
| IngestDate | Wed Oct 01 14:42:09 EDT 2025 Mon Jul 21 06:05:37 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | NCDs cardiovascular disease essential medicines WHO Essential Medicines List |
| Language | English |
| License | Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c490t-bfcd1eda2e68727ae299a7aef365976b30faa1757a29b2d031dd9754a6a30b672 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0735109717417827 |
| PMID | 29406862 |
| PQID | 1999192151 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1999192151 pubmed_primary_29406862 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-06 |
| PublicationDateYYYYMMDD | 2018-02-06 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-06 day: 06 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of the American College of Cardiology |
| PublicationTitleAlternate | J Am Coll Cardiol |
| PublicationYear | 2018 |
| SSID | ssj0006819 |
| Score | 2.4668202 |
| SecondaryResourceType | review_article |
| Snippet | The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 564 |
| SubjectTerms | Cardiovascular Diseases - prevention & control Drugs, Essential - therapeutic use Formularies as Topic Humans World Health Organization |
| Title | Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29406862 https://www.proquest.com/docview/1999192151 |
| Volume | 71 |
| WOSCitedRecordID | wos000423996800012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhKrIXESO5kQKq0YaNUBpG7VObYlGJJCCgPix3OOExUGJCSWZIoVnb_cffHdd0fIhVEilQpyhvCxLOZcskxmwFKhVQgAKoqhHjYhR6N0MsnGzYFb1ZRVtj6xdtS6zN0Z-ZWTy7veXUl4PXthbmqUy642IzSWSSdCKuNQLSeLbuEirQd7YMhMWYTMuRHN-PquZ8hdC8NQXrounon4nWLWoWaw-d-X3CIbDcmkNx4V22TJFDtkbdik0XfJp5-A9vSBcYsiA6R1SQ31kiT6XZ5J7xEGtLS0XzmVEoKVtstUFPkubVtA4UJQaNrzle9O4057P0pd6a1PBVV75HHQf-jdsWYMA8vjLJgzZXMdGg3c4LZyCQYjGODNRgJtKlQUWABkIRJ4prhGL6F1JpMYBESBEpLvk5WiLMwhocLqUEVJbi3-hmktQMkA6b0OtJXWWNkl561dpwhzl7uAwpRv1XRh2S458Jsznfl-HFOexbXQ5egPTx-TddzztK67FiekY_EjN6dkNX-fP1WvZzV-8DoaD78AWU_TGA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modernizing+the+World+Health+Organization+List+of+Essential+Medicines+for+Preventing+and+Controlling+Cardiovascular+Diseases&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Kishore%2C+Sandeep+P&rft.au=Blank%2C+Evan&rft.au=Heller%2C+David+J&rft.au=Patel%2C+Amisha&rft.date=2018-02-06&rft.issn=1558-3597&rft.eissn=1558-3597&rft.volume=71&rft.issue=5&rft.spage=564&rft_id=info:doi/10.1016%2Fj.jacc.2017.11.056&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-3597&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-3597&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-3597&client=summon |